Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a rare disease called Atypical Hemolytic Uremic Syndrome (aHUS), which affects the blood and kidneys. The study is testing a treatment called Crovalimab, which is given as a solution for injection or infusion. The purpose of the study is to evaluate how effective and safe Crovalimab is for children who have not received any previous treatment that inhibits a part of the immune system known as the complement system.

Participants in the study will receive Crovalimab and will be monitored over a period of time to see how their condition responds to the treatment. The study will look at various health indicators, such as kidney function and blood parameters, to determine the treatment's impact. The study will also monitor any side effects or reactions to the treatment, including those at the injection site or related to the immune system.

The study aims to gather information on how well Crovalimab works in managing aHUS and its potential benefits and risks. This information will help in understanding the treatment's effectiveness and safety for children with this condition. The study is expected to continue until 2029, providing valuable insights into the management of aHUS in pediatric patients.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying vaccination against Neisseria meningitidis within the last three years and ensuring compliance with local guidelines for patients with complement deficiency.

    For female patients of childbearing potential, a commitment to abstain from heterosexual intercourse or use contraception is required.

  2. Step 2

    Treatment initiation

    The treatment involves the administration of crovalimab, a solution for injection or infusion. The medication is given through subcutaneous (under the skin) and intravenous (into a vein) routes.

    The first dose is administered after confirming the onset of initial TMA (thrombotic microangiopathy) presentation within 28 days prior to the first dose for treatment-naive patients.

  3. Step 3

    Treatment phase

    The treatment phase lasts for 24 weeks. During this period, the effect of crovalimab is monitored through various parameters, including kidney function and blood tests.

    Regular assessments are conducted to evaluate the response to treatment, including changes in dialysis requirements, kidney function, and blood parameters.

  4. Step 4

    Monitoring and evaluation

    Throughout the study, the incidence and severity of any adverse events, including injection site reactions and infections, are closely monitored.

    The presence of anti-drug antibodies (ADAs) to crovalimab is also assessed to understand the body's immune response to the medication.

  5. Step 5

    Completion of treatment

    At the end of the 24-week treatment period, a final evaluation is conducted to determine the overall effectiveness of the treatment.

    The study aims to measure the proportion of patients achieving a complete TMA response and maintaining TMA control from baseline through Week 25.

Who can join the trial?

7 criteria

  • The patient must have been vaccinated against Neisseria meningitidis (a type of bacteria) within the last 3 years before starting the study treatment. This is important for patients with a condition called complement deficiency, which affects the immune system.
  • If the patient is a female who can have children, she must agree to either not have heterosexual intercourse or use birth control during the study.
  • For patients who have not received treatment before (naive cohort), the first signs of a condition called TMA (a type of blood disorder) must have appeared within 28 days before the first dose of the study medication, crovalimab.
  • For patients switching from other treatments (switch cohort), there must be clinical evidence showing a response to either eculizumab or ravulizumab. This is shown by a platelet count that is normal or higher, LDH (a type of enzyme) that is normal or lower, and stable or improving kidney function, measured by creatinine levels, in two tests at least 4 weeks apart before starting crovalimab.
  • For patients in the C5SNP cohort, they must have a known C5 polymorphism (a genetic variation), such as Arg885.
  • The study is open to both male and female patients.
  • The study includes patients who are considered a vulnerable population, which means they may need special protection or care.

Who cannot join the trial?

8 criteria

  • Patients who have previously received treatment with a complement inhibitor. A complement inhibitor is a type of medication that affects a part of the immune system called the complement system.
  • Patients with any other medical condition that the study doctors believe would make it unsafe for them to participate.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial within a certain period before this study.
  • Patients with a history of severe allergic reactions to any of the study medications.
  • Patients with certain infections that could interfere with the study.
  • Patients with a history of drug or alcohol abuse that could affect their ability to participate in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Crovalimab is a medication being studied for its effects on pediatric patients with atypical Hemolytic Uremic Syndrome (aHUS). This condition is a rare disease that affects the blood and kidneys. Crovalimab works by inhibiting a part of the immune system called the complement system, which is thought to play a role in the development of aHUS. The trial aims to assess how well Crovalimab works, its safety, and how it behaves in the body of patients who have not previously received treatment with complement inhibitors.

What is already known about the treatment

Crovalimab – Crovalimab is administered as an injection, typically given under the skin. It is currently being studied in clinical trials, particularly for its effectiveness and safety in treating pediatric patients with Atypical Hemolytic Uremic Syndrome (aHUS). The main therapeutic indication for Crovalimab is to manage aHUS, a rare disease that affects the blood and kidneys. At the molecular level, Crovalimab works by inhibiting a part of the immune system known as the complement system, which is overactive in aHUS. It is classified pharmacologically as a complement inhibitor.

Investigated diseases

Atypical Hemolytic Uremic Syndrome (aHUS) – Atypical Hemolytic Uremic Syndrome is a rare condition characterized by the formation of small blood clots in the blood vessels, which can lead to damage in various organs, particularly the kidneys. It is caused by the abnormal activation of the complement system, a part of the immune system. This disease often results in hemolytic anemia, where red blood cells are destroyed faster than they can be made, leading to fatigue and weakness. Patients may also experience thrombocytopenia, a condition where there are fewer platelets in the blood, increasing the risk of bleeding. Kidney function can be severely affected, potentially leading to acute kidney injury or chronic kidney disease. The progression of aHUS can vary, with some individuals experiencing frequent relapses and others having a more stable course.
Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IIITrial ID2023-505638-82-00Protocol codeBO42354Estimated enrolment38 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.